Close
CDMO Safety Testing 2026
Novotech

OTTR First to Provide Management Software for Immune Effector Cell (IEC) Cancer Treatment

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Cantex and Headlamp Target MS Depression Using Lumos AI

Cantex Pharmaceuticals and Headlamp Health have entered a collaboration...

VoxCell and adMare Partner on Antibody Therapy Research

VoxCell BioInnovation Inc. and adMare BioInnovations have entered a...
- Advertisement -

OTTR, the leading provider of solid organ transplant and cellular therapy patient tracking software, is introducing a new module for immune effector cells (IEC) within its CompleteCellular solution.

IEC is a promising category of cancer treatment — such as chimeric antigen receptor (CAR) T-cell therapy — that offers alternatives to patients who have a disease that is relapsed and/or refractory to standard treatment options, such as surgery, chemotherapy and radiation therapy.

“With the growth of next-generation cancer treatments such as IEC-based therapies, clinical programs have been looking for suitable software solutions,” said Linda Laub, RN, MSN, MSHCI, vice president of the cellular therapy account at OTTR. “Our new module —one of the first of its kind designed specifically to support IEC — will help optimize patient safety and increase efficiency while facilitating regulatory compliance for IEC teams.”

The most common therapy utilizing IEC, CAR T-cell therapy, entails re-introduction of a strain of a patient’s own T cells — a type of white blood cell — after they have been genetically modified to specifically bind and kill the cancer cells.

While CAR T-cell therapy and other IEC therapies are distinct from bone marrow transplant (BMT), the patient care, management and regulations for these modalities bear many similarities. The treatments are complex and require lengthy and intense monitoring, resulting in the collection and tracking of large amounts of data for safety and regulatory purposes. For OTTR, with its well-known BMT management solutions, developing software for IEC was a logical step.   

Find OTTR at Booth 219 at Cerner Health Conference, Oct. 8-11, Kansas City, Mo. To learn more about the newly launched IEC module and other complete transplant management solutions for improving patient care, managing workflows and creating operational efficiencies, visit OTTR at CHC or schedule a demo.

About OTTR
Since 1993, OTTR has provided transplant software solutions that improve the quality of patient care via workflow management to reduce operational costs. As the leading provider of solid organ transplant and cellular therapy patient tracking software, OTTR serves over 200 programs at more than 60 transplant centers in the U.S. and Canada, and also offers software solutions in the U.K., Saudi Arabia and Australia. OTTR’s English-language-based solutions are customized to support various international regulatory models. For more information, visit ottr.com.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Cantex and Headlamp Target MS Depression Using Lumos AI

Cantex Pharmaceuticals and Headlamp Health have entered a collaboration...

VoxCell and adMare Partner on Antibody Therapy Research

VoxCell BioInnovation Inc. and adMare BioInnovations have entered a...

Avenda Health Expands Unfold AI Into Midwest Cancer Care

Avenda Health said the University of Michigan Health Weiser...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »